| Hyperlipidemia |
Goal LDL <100 mg/dL or 30–40% reduction from baseline |
No specific goal for LDL cholesterol, consider measuring lipids to assess adherence to medication regimen |
| Treatment consists of dietary modifications |
Treatment consists of dietary modifications |
| Statins are recommended in patients with overt CVD and those over the age of 40 years with another risk factor for CVD |
Statin or statin-ezetimibe combination is recommended in patients with nondialysis-dependent CKD |
| For high-CVD-risk patients, <70 mg/dL is an option |
Reduced doses of statins are recommended for eGFR <60 mL/min/1.73 m2
|
| Initiation of statin therapy has not been shown to be beneficial in patients undergoing chronic dialysis treatment |
| Statins may reduce CVD risk in kidney transplant recipients |
| Hypertension |
Goal BP is <140/80 mmHg |
Goal BP is <140/90 mmHg |
| Treatment consists of lifestyle modifications and oral medications that generally should include RAAS blockers |
Goal BP is <130/80 mmHg if urine ACR >30 mg/g creatinine |
| Goals for treatment are based primarily on studies of patients with nondiabetic CKD |
| Treatment consists of lifestyle modifications and oral medications that usually include RAAS blockers |
| Use of more than one RAAS blocker should generally be avoided |
| Hyperglycemia |
Goal is A1C <7% |
A1C <8% when GFR <60 mL/min/1.73 m2 due to increased risks of hypoglycemia |
| A goal of <6.5% may be appropriate in early-onset diabetes in younger patients |
Imprecision of A1C with CKD strengthens reliance of SMBG in making treatment decisions |
| Treatment consists of lifestyle modification, oral medications, and injectable medications, including insulin |
Doses of insulin and other injectable and oral medications used to lower blood glucose often need to be reduced for eGFR <60 mL/min/1.73 m2
|
